Current Headlines

  1. FDA Accepts New Drug Application For VX-445 (Elexacaftor), Tezacaftor And Ivacaftor Combination Treatment
    8/20/2019

    Vertex Pharmaceuticals Incorporated recently announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for the VX-445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen

  2. Alligator Bioscience Signs Antibody Agreement For Greater China With Biotheus Inc.
    8/20/2019

    Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. ("Biotheus"), a privately held Chinese company based in Zhuhai, Guangdong, China

  3. FDA Approves New Antibiotic To Treat Community-Acquired Bacterial Pneumonia
    8/19/2019

    "This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease," said Ed Cox, M.D., M.P.H., director of FDA's Office of Antimicrobial Products

  4. Discovery Of Anti-Opioid Pathway Offers New Route To Designing Safer Pain Medications
    8/16/2019

    A team at Scripps Research in Florida has discovered a biological system that manages cells’ response to opioid drug exposure. The unexpected discovery offers new ideas for improving the safety of the one of the most effective, and most abused, group of pain medications

  5. ALS Drug Grant To Spur Drug Discovery At Northwestern
    8/16/2019

    Two Northwestern University scientists have received a $3.1M grant from the National Institute on Aging to collaborate and investigate drug therapies for amyotrophic lateral sclerosis (ALS)

  6. GeneCentric Therapeutics Acquires Select ImmunoGenomics
    8/15/2019

    GeneCentric Therapeutics, Inc. recently announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs

  7. FDA Approves Third Oncology Drug That Targets A Key Genetic Driver Of Cancer, Rather Than A Specific Type Of Tumor
    8/15/2019

    The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments

  8. Neuropore Receives Orphan Drug Designation For NPT520-34 For The Treatment Of Amyotrophic Lateral Sclerosis
    8/14/2019

    Neuropore Therapies, Inc. announced recently that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS

  9. Charcoal-Based Drug Delivery System Improves Efficacy Of Common Herpes Drug
    8/14/2019

    A study led by researchers from the University of Illinois at Chicago has found that combining acyclovir — a commonly prescribed topical herpes medication — with particles of activated carbon improves efficacy of the drug

  10. Drug Accelerates Blood System’s Recovery After Chemotherapy, Radiation
    8/14/2019

    A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation and bone marrow transplants